Abstract
The current treatment of acute promyelocytic leukemia with arsenic trioxide (ATO) has increased long-lasting complete remissions; however, a proportion of patients continues to die eventually as a result of disease recurrence. In an effort to enhance the effectiveness of the APL treatment, we designed experiments to evaluate the effects of ATO in combination with the lead compound of non-nucleoside inhibitor of telomerase, BIBR 1532. After combined treatments with BIBR 1532 and ATO, decreased cell viability index with a concomitant increase in apoptotic cell death was observed in NB4 leukemic cells. Apoptosis induced by the combined treatments was accompanied by elevated Bax/Bcl-2 molecular ratio and enhanced caspase 3 activation. Our study has also demonstrated that the combined treatment suppressed NB4 cell proliferative capacity and inhibited telomerase activity probably via transcriptional suppression of c-Myc and hTERT. In conclusion, this study may supply insight into the application of this new combination therapy to APL cells intrinsically less sensitive to routine therapies and suggested a novel combination therapy for patients with more aggressive disease; those who may not respond favorably to the arsenic mono-therapy.
Keywords: Arsenic trioxide, BIBR 1532, Telomerase, Acute promyelocytic leukemia, Apoptosis, Combination therapy.
Anti-Cancer Agents in Medicinal Chemistry
Title:BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL
Volume: 13 Issue: 7
Author(s): Davood Bashash, Seyed H.Ghaffari, Farhad Zaker, Maryam Kazerani, Kebria Hezave, Saeed Hassani, Masomeh Rostami, Kamran Alimoghaddam and Ardeshir Ghavamzadeh
Affiliation:
Keywords: Arsenic trioxide, BIBR 1532, Telomerase, Acute promyelocytic leukemia, Apoptosis, Combination therapy.
Abstract: The current treatment of acute promyelocytic leukemia with arsenic trioxide (ATO) has increased long-lasting complete remissions; however, a proportion of patients continues to die eventually as a result of disease recurrence. In an effort to enhance the effectiveness of the APL treatment, we designed experiments to evaluate the effects of ATO in combination with the lead compound of non-nucleoside inhibitor of telomerase, BIBR 1532. After combined treatments with BIBR 1532 and ATO, decreased cell viability index with a concomitant increase in apoptotic cell death was observed in NB4 leukemic cells. Apoptosis induced by the combined treatments was accompanied by elevated Bax/Bcl-2 molecular ratio and enhanced caspase 3 activation. Our study has also demonstrated that the combined treatment suppressed NB4 cell proliferative capacity and inhibited telomerase activity probably via transcriptional suppression of c-Myc and hTERT. In conclusion, this study may supply insight into the application of this new combination therapy to APL cells intrinsically less sensitive to routine therapies and suggested a novel combination therapy for patients with more aggressive disease; those who may not respond favorably to the arsenic mono-therapy.
Export Options
About this article
Cite this article as:
Bashash Davood, H.Ghaffari Seyed, Zaker Farhad, Kazerani Maryam, Hezave Kebria, Hassani Saeed, Rostami Masomeh, Alimoghaddam Kamran and Ghavamzadeh Ardeshir, BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/18715206113139990126
DOI https://dx.doi.org/10.2174/18715206113139990126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Formation of Five- and Six-Membered α,β-Unsaturated Lactones through Ring- Closing Metathesis of Functionalized Acrylates. Applications to Synthesis of Natural Products
Current Organic Chemistry The Mammalian Innate Immune System: Potential Targets for Drug Development
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cell Responses to Oxidative Stressors
Current Pharmaceutical Design MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research Roles of Growth Factors in Chemotherapy-Induced Intestinal Mucosal Damage Repair
Current Pharmaceutical Biotechnology Colloidal Drug Delivery Systems in Vaccine Delivery
Current Drug Targets Analytical Methods for Metallothionein Detection
Current Analytical Chemistry 10 Years of SELDI: What Have we Learnt?
Current Proteomics Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Electrocatalytic Determination of 6-Mercaptopurine Using Multiwall Carbon Nanotubes Paste Electrode in the Presence of Methyldopa
Current Nanoscience Biodegradable Nanoparticles: A Recent Approach and Applications
Current Drug Targets Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Porphyrin Metabolisms in Human Skin Commensal Propionibacterium acnes Bacteria: Potential Application to Monitor Human Radiation Risk
Current Medicinal Chemistry Lung Cancer Stem Cells: An Epigenetic Perspective
Current Cancer Drug Targets Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews